Loading stock data…
Pacific Biosciences of California (PACB)
$1.73+0.08 (+4.85%)
Market ClosedLast close Jun 29
Pacific Biosciences of California, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pacific Biosciences of California, Inc. in the Healthcare sector is trading at $1.73 with a market capitalization of $427M. Wall Street consensus targets $2.46 (6 analysts), implying a +42.1% move over the next 12 months. The stock is currently 37% below its 52-week high of $2.73, remaining 2.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +42.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $37.18M↓ | $44.65M↑ | $38.44M↓ | $39.77M↑ | $37.15M |
| Gross Profit | $12.84M↓ | $16.57M↑ | $15.90M↑ | $14.68M↑ | -$1.37M |
| Operating Income | -$54.15M↓ | -$41.20M↓ | -$38.88M↑ | -$44.85M↑ | -$432.63M |
| Net Income | -$8.28M↑ | -$40.37M↓ | -$38.00M↑ | -$41.93M↑ | -$426.07M |
Peer Comparison
JNJUNHPFE
Fundamentals
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technol...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$427.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-5434.32%
Volume
Today's trading volume
8.29M
Recent News
PacBio (PACB) Stock Faces Mixed Analyst Target Changes After Valuation Revisions
Pacific Biosciences of California is back in focus as analysts adjust their price targets by increments of $0.50, reflecting fresh views on what the stock could reasonably be worth. Some on the Street see the higher targets as a sign of growing comfort with PacBio’s execution, while others trimming their targets are signaling more caution around the company’s ability to meet prior expectations. As you read on, you will see how these conflicting calls shape the evolving narrative and what to...
Is Pacific Biosciences of California, Inc. (PACB) One of the Best Genomics Stocks to Buy According to Wall Street?
Pacific Biosciences of California, Inc. (NASDAQ:PACB) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On May 26, Pacific Biosciences of California, Inc. (NASDAQ:PACB) began global shipments of its SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for the Revio platform. The firm lowered the per-genome list price to $345 and authorized […]
Cathie Wood Buys $444 Million in SpaceX, Dumps Tesla and AMD
Cathie Wood Dumps Tesla. Her New Favorite Is SpaceX
3 Unprofitable Stocks That Concern Us
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.31, moving 2.96% from the previous trading session.